Angelini Pharma

Brain physiology
#Angelini Pharma #Biopharma #Brain #Mergers and acquisitions

Angelini Pharma acquires Catalyst to enter US market 

Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion.  Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market… Read More

#Business & Investment #News